Three Year Parkinson’s Study Validates Use of Wearable Technology to Track Real World Disease Progression

A new C-Path study identifies gait and balance as key burdens in early Parkinson’s, using wearable tech to revolutionize patient-focused drug development.

By: AXL Media

Published: Mar 11, 2026, 5:40 AM EDT

Source: The information in this article was sourced from Critical Path Institute (C-Path)

Bridging the Gap Between Clinical Data and Patient Experience

The Critical Path Institute (C-Path) has announced the publication of a three-year prospective study that fundamentally redefines how the medical community observes early Parkinson’s disease (PD) progression. Led by Dr. Jamie Adams and Dr. Jennifer Mammen, the research emphasizes a shift toward patient-focused drug development by integrating the "lived experience" of participants into the formal scientific record. According to the study published in the Journal of Neurology, traditional clinical observations often fail to capture the full scope of functional decline. By centering the patient voice, the research team aims to ensure that future therapeutic interventions address the specific impacts that individuals find most bothersome in their daily lives.

The Evolving Burden of Gait and Postural Stability

Over the course of thirty-six months, the study tracked participants to identify which symptoms exerted the heaviest toll on their quality of life. The findings indicate that issues related to gait, balance, and posture emerged as the primary concerns for those in the early stages of the disease. While some specific neurological symptoms might appear to stabilize during clinical check-ups, the actual effort required to perform routine daily activities increased significantly for the participants. This discrepancy highlights a critical need for new measurement standards that look beyond surface-level symptoms to assess the deeper psychosocial and physical burdens of the condition.

Leveraging Wearable Technology for Longitudinal Insights

Central to the study’s success was the implementation of digital health technologies, specifically wearable devices that monitored participants in real-world settings. Unlike periodic in-office evaluations, these tools provided a continuous stream of data regarding how Parkinson’s affects movement outside of a controlled environment. According to Diane Stephenson, Ph.D., of C-Path, providing drug developers with these robust, patient-centered measurement tools is essential for designing more efficient clinical trials. The data suggests that digital measures can capture subtle changes in mobility that traditional assessments might miss, offering a more granular view of how the disease advances over time.